Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Seroquel Lawsuits Cost AstraZeneca $200M

By Drug Discovery Trends Editor | August 9, 2010

LONDON (AP) – AstraZeneca PLC said it has reached agreements to pay a modest $198 million to settle a little over half of the U.S. lawsuits that allege its antipsychotic drug Seroquel caused diabetes and other harm.

AstraZeneca said the agreements cover roughly 17,500 claimants, out of the remaining 26,100 plaintiffs who have brought product liability lawsuits. That works out to an average of just $11,314 per plaintiff. The company has already disposed of 4,725 Seroquel cases.

The London-based company, the world’s sixth-largest drugmaker by revenue, said the eventual payouts won’t affect its 2010 profit forecast, which calls for earnings per share of $6.35 to $6.65.

“While the terms remain confidential and are subject to non-monetary agreements, we believe it was in the best interest of the company to explore resolving these cases through the mediation process,” company spokesman Tony Jewell told The Associated Press. “We remain committed to a strong defense effort, but will also continue to participate in good faith in court-ordered mediation.”

Despite all the lawsuits, Seroquel is still AstraZeneca’s second-biggest seller after its Nexium ulcer drug. Seroquel generated sales of $4.9 billion last year, or 15 percent of the company’s revenue.

It and about a half-dozen other powerful, heavily promoted psychiatric drugs that are officially approved for treating schizophrenia and bipolar disorder are widely prescribed for unapproved uses, including depression and insomnia. They also have been inappropriately given to some children and elderly patients.

All that so-called “off-label” use has made these newer antipsychotic treatments the industry’s seventh-best-selling class of drugs, with global sales last year of more than $23 billion. That’s up 50 percent in just four years.

AstraZeneca’s new settlements follow a July order from the U.S. Food and Drug Adminisation that the company stop using a promotional letter for Seroquel XR – an extended release version of the medicine – that doesn’t carry a diabetes warning.

Lawyers for many patients who took Seroquel have alleged that AstraZeneca officials kept its dangers secret for years.

The company has denied that repeatedly, and has fought hard to keep internal company documents about the drug’s risks from becoming public. It also has gone to great pains to reassure investors that the litigation won’t be a big hit to the company – unlike the $4.85 billion that American rival Merck & Co. paid out to settle product liability suits over its former pain reliever Vioxx.

As of the end of June, 2,900 cases have been dismissed by court order or agreement between AstraZeneca and the plaintiffs. Another 1,825 cases were dismissed with prejudice, which means they can be refiled later.

Date: August 9, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50